AR114269A1 - Secuencias nucleotídicas mejoradas que codifican para péptidos de unión - Google Patents

Secuencias nucleotídicas mejoradas que codifican para péptidos de unión

Info

Publication number
AR114269A1
AR114269A1 ARP190100462A ARP190100462A AR114269A1 AR 114269 A1 AR114269 A1 AR 114269A1 AR P190100462 A ARP190100462 A AR P190100462A AR P190100462 A ARP190100462 A AR P190100462A AR 114269 A1 AR114269 A1 AR 114269A1
Authority
AR
Argentina
Prior art keywords
nucleotytic
enhanced
sequences coding
nucleotide
nucleic acid
Prior art date
Application number
ARP190100462A
Other languages
English (en)
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of AR114269A1 publication Critical patent/AR114269A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan secuencias de nucleótidos y ácidos nucleicos mejorados que codifican enlazadores de glicina y serina y que utilizan un exceso de codones GGA, GGG y GGT / GGU para codificar los residuos de glicina. Además a secuencias de nucleótidos y ácidos nucleicos que codifican proteínas y polipéptidos (de fusión) que comprenden enlazadores de glicina y serina, donde las secuencias de nucleótidos y los ácidos nucleicos comprenden tales secuencias de nucleótidos y ácidos nucleicos mejorados de la presente.
ARP190100462A 2018-02-26 2019-02-26 Secuencias nucleotídicas mejoradas que codifican para péptidos de unión AR114269A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862634985P 2018-02-26 2018-02-26

Publications (1)

Publication Number Publication Date
AR114269A1 true AR114269A1 (es) 2020-08-12

Family

ID=65635665

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100462A AR114269A1 (es) 2018-02-26 2019-02-26 Secuencias nucleotídicas mejoradas que codifican para péptidos de unión

Country Status (7)

Country Link
US (1) US20200392512A1 (es)
EP (1) EP3758755A1 (es)
JP (1) JP7266611B2 (es)
CN (1) CN111655296A (es)
AR (1) AR114269A1 (es)
TW (1) TW202000238A (es)
WO (1) WO2019162521A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2162878A1 (en) 1993-06-09 1994-12-22 Leon Gerardus Joseph Frenken Process for producing fusion proteins comprising scfv fragments by a transformed mould
ATE400651T1 (de) 1993-09-10 2008-07-15 Univ Columbia Verwendung von grünem fluoreszenzprotein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
DE69604298T2 (de) 1995-09-22 2000-05-18 Bioimage A/S, Soeborg Varianten des grünen fluoreszenzproteins, gfp
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
BR9907950A (pt) 1998-02-19 2001-12-18 Xcyte Therapies Inc Composições e processos para regulagem deativação de linfócitos
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
EP1373501A2 (en) 2000-10-06 2004-01-02 Novartis AG Targeting molecules for adenoviral vectors
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
US7207410B2 (en) 2004-04-29 2007-04-24 Daimlerchrysler Corporation Apparatus and method for enhanced impact sensing
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CN102311503A (zh) 2007-06-06 2012-01-11 天津溥瀛生物技术有限公司 对多种皮肤细胞修复具持续作用的重组人血清白蛋白/fgf融合蛋白
WO2009068625A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
JP5771147B2 (ja) * 2008-09-26 2015-08-26 トカジェン インコーポレーテッド 遺伝子治療ベクターおよびシトシンデアミナーゼ
PE20130527A1 (es) 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
US20150158948A9 (en) * 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
HUE047238T2 (hu) * 2011-06-23 2020-04-28 Ablynx Nv Szérumalbuminhoz kötõdõ fehérjék
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
KR20150036606A (ko) 2012-07-13 2015-04-07 자임워크스 인코포레이티드 항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체
CN104277118A (zh) 2014-07-14 2015-01-14 天津科技大学 重组人骨形态发生蛋白异源二聚体蛋白及高效表达和复性方法
SI3037530T1 (sl) * 2014-12-22 2017-05-31 Sandoz Ag Variante sekvenc
US10765699B2 (en) * 2015-02-06 2020-09-08 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
CN107557341B (zh) 2017-09-30 2020-06-30 山东兴瑞生物科技有限公司 一种抗wt1增强型嵌合抗原受体修饰的免疫细胞及其应用

Also Published As

Publication number Publication date
CN111655296A (zh) 2020-09-11
EP3758755A1 (en) 2021-01-06
WO2019162521A1 (en) 2019-08-29
JP7266611B2 (ja) 2023-04-28
US20200392512A1 (en) 2020-12-17
JP2021514638A (ja) 2021-06-17
TW202000238A (zh) 2020-01-01

Similar Documents

Publication Publication Date Title
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
EA202091198A1 (ru) Полипептиды, содержащие домен d, и их применение
AR114339A1 (es) Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus
AR116173A1 (es) Agentes de unión a psma y usos de estos
AR081454A1 (es) Proteinas de dominio de armazon basadas en fibronectina que se unen a pcsk9 (proproteina convertasa subtilisina kexina 9)
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
ECSP19011185A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
MX2021000047A (es) Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
CO7131365A2 (es) Factores de coagulación de acción prolongada y métodos de producción de los mismos
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
CL2023000752A1 (es) Composiciones y métodos para tratar la enfermedad celiaca
AR114269A1 (es) Secuencias nucleotídicas mejoradas que codifican para péptidos de unión
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
BR112021020447A2 (pt) Métodos e usos de proteínas de fusão de ligante icos variante (icosl)
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
EA202090404A1 (ru) Универсальный способ презентирования циклического пептида на белковой структуре
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
CL2024000387A1 (es) Anticuerpos anti-cd63, conjugados y usos de estos
CR20180008A (es) Variantes de il-37
CO2023017249A2 (es) Proteínas de fusión tnfsf-l y usos de las mismas
CU20200064A7 (es) Expresión de la proteína de superficie neumocócica a (pspa)
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes